NYSE: ADCTAdc Therapeutics Sa Stock
$3.58-0.09 (-2.45%)
Updated Jun 13, 2025
ADCT Price
$3.58
Fair Value Price
N/A
Market Cap
$355.06M
52 Week Low
$1.05
52 Week High
$4.13
P/E
-2.5x
P/B
-1.49x
P/S
1.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$75.82M
Earnings
-$149.84M
Gross Margin
92.7%
Operating Margin
-131.54%
Profit Margin
-197.6%
Debt to Equity
-2.14
Operating Cash Flow
-$136M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADCT Overview
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADCT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADCT
Ranked#117 of 464
Ranked#117 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important ADCT news, forecast changes, insider trades & much more!
ADCT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADCT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADCT is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ADCT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ADCT due diligence checks available for Premium users.
Valuation
ADCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.5x
Industry
-108.97x
Market
31.36x
ADCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.49x
Industry
4.66x
ADCT's financial health
Profit margin
Revenue
$23.0M
Net Income
-$38.6M
Profit Margin
-167.6%
ADCT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ADCT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$272.5M
Liabilities
$510.8M
Debt to equity
-2.14
ADCT's short-term assets ($257.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADCT's long-term liabilities ($452.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADCT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$56.3M
Investing
-$264.0k
Financing
$271.0k
ADCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADCT vs Biotech Stocks
Adc Therapeutics Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.